Smoking and antidepressants pharmacokinetics: a systematic review
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite an increasingly recognized relationship between depression and smoking, little is known about how smoking influences antidepressant response and treatment outcomes. The aim of this study was to systematically review the evidence of the impact of smoking on new-generation antidepressants with an emphasis on the pharmacokinetic perspective. METHODS: We present a systematic review of clinical trials comparing the serum levels of new-generation antidepressants in smokers and nonsmokers. Data were obtained from MEDLINE/PubMed, Embase, and other sources. Risk of bias was assessed for selection, performance, detection, attrition, and reporting of individual studies. RESULTS: Twenty-one studies met inclusion criteria; seven involved fluvoxamine, two evaluated fluoxetine, sertraline, venlafaxine, duloxetine or mirtazapine, and escitalopram, citalopram, trazodone and bupropion were the subject of a single study. No trials were found involving other common antidepressants such as paroxetine or agomelatine. Serum levels of fluvoxamine, duloxetine, mirtazapine and trazodone were significantly higher in nonsmokers compared with smokers. CONCLUSIONS: There is evidence showing a reduction in the concentration of serum levels of fluvoxamine, duloxetine, mirtazapine and trazodone in smoking patients as compared to nonsmokers. The evidence regarding other commonly used antidepressants is scarce. Nonetheless, smoking status should be considered when choosing an antidepressant treatment, given the risk of pharmacokinetic interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Tobacco smoking [43], alcohol consumption [44], fasting [55], and concomitant drug use [56, 57] may influence antidepressant metabolization and thus the bioavailability of the drugs”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,171
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221 · cited 1×
“It has been projected to become the leading cause of disability and the second leading contributor to the global burden of disease and overall mortality by the year 2020; according to the recent epidemiologic data, about 10% of world population suffers with depression [3].”
BackgroundAGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Drug Interactions with Tobacco Smoking: An Update
Zevin, S., & Benowitz, N. L. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00004 · Cited by 692
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1189 · Cited by 579 · cited 1×
“Background One-quarter of the general population, 40–50% of people with depression and 70–80% of those with schizophrenia smoke [1, 2].”
BackgroundPharmacogenetics, Pharmacogenomics, and Individualized Medicine
Ma, Q., & Lu, A. Y. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003533 · Cited by 464 · cited 1×
“Different antidepressants are metabolized by different subtypes of CYP and the amount of each CYP varies from person to person [6].”
BackgroundWhy do patients with schizophrenia smoke?
Winterer, G. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283366643 · Cited by 240 · cited 1×
“Background One-quarter of the general population, 40–50% of people with depression and 70–80% of those with schizophrenia smoke [1, 2].”
BackgroundMuth, E. A., Moyer, J. A., Haskins, J. T., Andree, T. H., & Husbands, G. E. M. (1991) · Drug Development Research · doi:10.1002/ddr.430230210 · Cited by 212 · cited 1×
“However, the pharmacodynamical effects of this are not completely understood, though many studies point to considerably weaker inhibition of serotonin and noradrenaline reuptake pumps when compared with venlafaxine itself [34].”
Background
Research works printed but not linked: 1
- Bastos H, Polido F, Saraiva C. História da Psiquiatria. In: Saraiva C, Cerejeira J, editors. Psiquiatria fundamental. Coimbra: Lidel Edições Técnicas; 2014.
Cited by
Marx, W., Manger, S. H., Blencowe, M., Murray, G., Ho, F. Y.-Y., Lawn, S., Blumenthal, J. A., Schuch, F., Stubbs, B., Ruusunen, A., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2112074 · Cited by 179
“pine, olanzapine, fluvoxamine, duloxetine, mirtazapine, and trazodone) (Oliveira et al. 2017).”
BackgroundDodd, S., Bauer, M., Carvalho, A. F., Eyre, H., Fava, M., Kasper, S., Kennedy, S. H., Khoo, J.-P., Lopez Jaramillo, C., Malhi, G. S., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1851052 · Cited by 88
“etine, mirtazapine and trazadone due to enzyme induction (Oliveira et al. 2017).”
BackgroundSørensen, A., Ruhé, H. G., & Munkholm, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01285-w · Cited by 65
Causes of drug discontinuation in patients with major depressive disorder in China
Zhu, Y., Wu, Z., Sie, O., Cai, Y., Huang, J., Liu, H., Yao, Y., Niu, Z., Wu, X., Shi, Y., et al. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109755 · Cited by 64
Couto, R. A. S., Gonçalves, L. M., Carvalho, F. D., Rodrigues, J. A., Rodrigues, C. M. P., & Quinaz, M. B. (2018) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2018.1439724 · Cited by 57
Metadata
- Authors
- Oliveira, P., Ribeiro, J., Donato, H., & Madeira, N.
- Affiliations
- Unidade Local de Saúde de Coimbra (PT)
- Corresponding author
- Madeira, Nuno
- Venue
- Annals of General Psychiatry
- Published
- 2017-03-06
- Volume
- 16
- Issue
- 1
- Pages
- 17-17
- ISSN
- 1744-859X (ISSN-L)
- PMC
- PMC5340025
- OpenAlex
- W2593668513
- Cited by
- 60
- References
- 41
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 8 · 2023: 5 · 2022: 6 · 2021: 8 · 2020: 7 · 2019: 8 · 2018: 7 · 2017: 1
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Annals of General Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- smoking, antidepressants, pharmacokinetics, drug interactions, depression, fluvoxamine, duloxetine, mirtazapine, trazodone, fluoxetine, sertraline, venlafaxine, escitalopram, citalopram, bupropion, serum drug concentration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Smoking and antidepressants pharmacokinetics: a systematic review. https://app.cochat.ai/papers/10.1186/s12991-017-0140-8
- The paper
- Oliveira, P., Ribeiro, J., Donato, H., & Madeira, N. (2017). Smoking and antidepressants pharmacokinetics: a systematic review. Annals of General Psychiatry. https://doi.org/10.1186/s12991-017-0140-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
